These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 22119203

  • 1. Targeting Raf/MEK/ERK pathway in pituitary adenomas.
    Suojun Z, Feng W, Dongsheng G, Ting L.
    Eur J Cancer; 2012 Feb; 48(3):389-95. PubMed ID: 22119203
    [Abstract] [Full Text] [Related]

  • 2. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ, Der CJ.
    Oncogene; 2007 May 14; 26(22):3291-310. PubMed ID: 17496923
    [Abstract] [Full Text] [Related]

  • 3. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
    McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, Steelman LS.
    Curr Opin Investig Drugs; 2008 Jun 14; 9(6):614-30. PubMed ID: 18516761
    [Abstract] [Full Text] [Related]

  • 4. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 5. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C, Settleman J.
    Cancer Lett; 2009 Oct 08; 283(2):125-34. PubMed ID: 19217204
    [Abstract] [Full Text] [Related]

  • 6. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 08; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 7. Targeting the ERK signaling pathway in cancer therapy.
    Kohno M, Pouyssegur J.
    Ann Med; 2006 Aug 08; 38(3):200-11. PubMed ID: 16720434
    [Abstract] [Full Text] [Related]

  • 8. Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?
    Cristea S, Sage J.
    J Thorac Oncol; 2016 Aug 08; 11(8):1233-1241. PubMed ID: 27133774
    [Abstract] [Full Text] [Related]

  • 9. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
    Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA.
    Leukemia; 2011 Jul 08; 25(7):1080-94. PubMed ID: 21494257
    [Abstract] [Full Text] [Related]

  • 10. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.
    Cakir M, Grossman AB.
    Expert Opin Ther Targets; 2009 Sep 08; 13(9):1121-34. PubMed ID: 19637976
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.
    Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J.
    J Eur Acad Dermatol Venereol; 2013 Jan 08; 27(1):11-8. PubMed ID: 22540151
    [Abstract] [Full Text] [Related]

  • 13. Emerging MEK inhibitors.
    McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M.
    Expert Opin Emerg Drugs; 2010 Jun 08; 15(2):203-23. PubMed ID: 20151845
    [Abstract] [Full Text] [Related]

  • 14. 1Alpha,25-dihydroxyvitamin D3-mediated stimulation of steroid sulphatase activity in myeloid leukaemic cell lines requires VDRnuc-mediated activation of the RAS/RAF/ERK-MAP kinase signalling pathway.
    Hughes PJ, Brown G.
    J Cell Biochem; 2006 Jun 01; 98(3):590-617. PubMed ID: 16440327
    [Abstract] [Full Text] [Related]

  • 15. Suppression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4.
    Yang YH, Wang Y, Lam KS, Yau MH, Cheng KK, Zhang J, Zhu W, Wu D, Xu A.
    Arterioscler Thromb Vasc Biol; 2008 May 01; 28(5):835-40. PubMed ID: 18340008
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
    Kramer BW, Götz R, Rapp UR.
    BMC Cancer; 2004 Jun 01; 4():24. PubMed ID: 15171791
    [Abstract] [Full Text] [Related]

  • 18. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity.
    Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R, Bernhagen J.
    Cell Signal; 2006 May 01; 18(5):688-703. PubMed ID: 16122907
    [Abstract] [Full Text] [Related]

  • 19. MEK-ERK signaling plays diverse roles in the regulation of facial chondrogenesis.
    Bobick BE, Kulyk WM.
    Exp Cell Res; 2006 Apr 15; 312(7):1079-92. PubMed ID: 16457813
    [Abstract] [Full Text] [Related]

  • 20. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 15; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.